Genmab (Otc) (GMAB) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Genmab’s TIVDAK has received full FDA approval for treating patients with recurrent or metastatic cervical cancer after showing an overall survival benefit in a Phase 3 study. TIVDAK is the first antibody-drug conjugate for this patient group that has demonstrated positive survival data compared to chemotherapy. This approval marks a significant advancement for women with advanced cervical cancer, offering a new treatment option where limited options existed before.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.